ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
Approximately 15% of men with very high-risk prostate cancer develop incurable distant metastases within five years of definitive treatment. Standard …
Post
-
-
ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
For GSK’s mocertatug rezetecan (Mo-Rez), the tumour microenvironment may predict response better than the target itself. B7-H4 has emerged as …
-
ESMO26: Oral cell cycle inhibitors place Cyclin E1 as new target in PROC
Cyclin E1 is emerging as a promising therapeutic target in platinum-resistant ovarian cancer (PROC), where conventional single-agent non-platinum chemotherapy has …
-
US targets Chinese biotech investment, but licensing deals remain exempt
The US government is seeking to curb American investment in Chinese firms involved in advanced drug development after adding the …
-
Egypt reforms obsolete pharmaceutical pricing framework
After nearly 15 years, Egypt’s pharmaceutical pricing framework has entered a new phase. In late September 2026, the Egyptian Drug …
-
Gilead spends $1.28bn on PepStar’s potential Icotyde rival
Gilead Sciences has inked a billion-dollar deal with Shanghai-based PepStar therapeutics to secure the global rights to an oral IL-23 …
-
Boehringer and Microsoft collaborate to explore AI in clinical research
Boehringer Ingelheim and Microsoft have entered a strategic collaboration to examine the use of AI in clinical research, beginning with …
-
Celltrion and Kaigene sign $580m licence deal for KG013
South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in …
-
Building the next generation of sustainable data centres in pharma
In the age of AI, pharma and tech companies are increasingly joining forces. Inevitably, such collaboration demands a strong digital …
-
CPHI 2026: Pharma manufacturers put AI to work
Predictive maintenance, virtual process development, and artificial intelligence (AI)-assisted quality management are creating practical opportunities for pharmaceutical manufacturers. But the …
-
Roche’s pharma sales grow 7% but pipeline trimmed down
Roche posted a healthy 7% growth for its pharmaceutical division in the first nine months of 2026, though the drugmaker …
-
Danish fast-track model inspires growth in national reimbursement rates
As of 1 June 2026, a novel assessment process for PD-(L)1 drugs was implemented in Denmark by the Danish Medicines …
-
Retatrutide peptide: A quality-control checklist for sourcing research-grade material
Few research compounds have drawn as much procurement traffic in the past two years as retatrutide. It is a single …
-
AstraZeneca bags another US indication for Ultomiris with IgAN approval
AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval …
-
Podcast: The impact of prediction markets on the clinical sector
Publicly traded drug developers have been exposed to insider trading on their stocks for decades, but with the introduction of …
